Chat with us, powered by LiveChat

SKYEPHARMA improves time to market

February 28, 2018 –


David LESCUYER – EVP Oral Business, Vectura Group of Companies – President of SKYEPHARMA PRODUCTION SAS:

“With over 20 years of experience in complex oral solid dosage forms, we help our customers on reformulation, Life Cycle Management, trouble shooting, scale up and technical transfer of their products.

Our state of the art equipment offers improved time to market for the whole value chain, benefiting our customers but more importantly and ultimately, patients.

We use Quality by Design tools focusing on “Right First Time” developments and robust processes.

From regular tablets to multi-layer, tab-in-tab, granules, hard capsules, we have the capabilities, we have the capacity and we have a great team that makes a difference to our customers”.

SKYEPHARMA continuously invests in its capabilities to ensure equipment coherence at all stages of the product’s life cycle:

SKYEPHARMA is able to handle offers state-of-the-art capabilities in complex oral solid dosage forms, whether they are multi-layer tablets, tab-in-tab, or even regular tablets.

More details about our new capabilities, please visit Skyepharma web site: